Fanny Cavalié, MBA

Chief Strategy Officer

Fanny Cavalié is the Chief Strategy Officer at GIVAX. As the CSO, Fanny leads GIVAX's corporate strategy and capital formation efforts, while establishing partnerships with investors and BioPharma companies to support the company's growth and portfolio development. In addition to her role at GIVAX, Fanny is also a Venture Partner at RA Ventures, focusing on new company creation. Fanny brings nearly twenty years of leadership experience in the life sciences industry, from drug discovery to commercial stages. Prior to joining RA, Fanny served as Chief Strategy and Business Operations Officer at Foghorn Therapeutics from 2018 to 2024. During her tenure, she built and led business functions, including corporate strategy, business development, alliance management, program leadership, commercial, corporate affairs and operations, in support of Foghorn’s IPO and growth into a clinical-stage company. Fanny also led the negotiation and operationalization of two key partnerships with Merck and Loxo@Lilly. Previously, Fanny spent four years at Biogen in various strategy and commercial positions, including Global Marketing lead for Alzheimer's Disease and Global Strategy Lead for the Multiple Sclerosis portfolio. Fanny also spent a decade at McKinsey in Europe, advising a diverse portfolio of BioPharma’s, payers, and providers. As Associate Partner and Co-leader of the EMEA Pharma Launch service line, she directed more than 50 projects encompassing strategy, organizational transformation, and product commercialization. Fanny holds an MBA from HEC in France.